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Abstract
Purpose – The purpose of this paper is to discuss overdose among those with criminal justice experience
and recommend harm reduction strategies to lessen overdose risk among this vulnerable population.
Design/methodology/approach – Strategies are needed to reduce overdose deaths among those
with recent incarceration. Jails and prisons are at the epicenter of the opioid epidemic but are a largely
untapped setting for implementing overdose education, risk assessment, medication assisted treatment,
and naloxone distribution programs. Federal, state, and local plans commonly lack corrections as an
ingredient in combating overdose. Harm reduction strategies are vital for reducing the risk of overdose in the
post-release community.
Findings – Therefore, the authors recommend that the following be implemented in correctional settings:
expansion of overdose education and naloxone programs; establishment of comprehensive medication assisted
treatment programs as standard of care; development of corrections-specific overdose risk assessment tools;
and increased collaboration between corrections entities and community-based organizations.
Originality/value – In this policy brief the authors provide recommendations for implementing harm
reduction approaches in criminal justice settings. Adoption of these strategies could reduce the number of
overdoses among those with recent criminal justice involvement.
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Background
Overdose epidemic
Globally, there has been a significant increase in drug-related overdose deaths in recent years
(Martins et al., 2015). Currently the USA is experiencing a growing number of overdose deaths.
In 2014, there were over 47,000 overdose deaths and the number of overdoses has increased
137 percent since 2000, making overdose the leading cause of accidental death (Rudd, Aleshire,
Zibbell, Gladden, 2016). Opioid-related deaths are largely responsible for the rise in overdose
fatalities; there was a 200 percent increase in the rate of overdoses involving opioids from 2000
to 2014 (Rudd, Aleshire, Zibbell, Gladden, 2016). In response, the Rudd, Seth, David, Scholl
(2016) has declared opioid-related overdoses a public health epidemic.
Over the past two decades, non-medical prescription opioid use has contributed substantially to
rising overdose rates (Calcaterra et al., 2013). In more recent years, though, national initiatives to
reduce opioid prescribing have produced modest declines in the number of prescription opioids
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dispensed (Dart et al., 2015). However, as the rate of opioid prescribing slowed there was a
subsequent increase in the rate of heroin-involved overdose suggesting that once addicted to
opioids, people are transitioning from non-medical prescription opioid use to heroin (Compton
et al., 2016). From 2010 to 2014, the rate of heroin-involved overdose deaths in the USA
increased three-fold (Compton et al., 2016).
Overdose among those with criminal justice experience
Individuals with a history of incarceration have an increased risk of overdose following release
from prison or jail (Binswanger et al., 2011; Merrall et al., 2010). In fact, a recent study found that
in Washington State overdose was the leading cause of death among those who were previously
incarcerated (Binswanger et al., 2013). In addition, recent research has demonstrated that more
than 80 percent of individuals who are incarcerated in local jails report issues with substance use
and almost half of all individuals in state-run correctional facilities have co-occurring mental illness
and substance dependence (James and Glaze, 2006).
The immediate post-release period is an especially high-risk time for a number of reasons. Return
to substance use after a period of abstinence while incarcerated can result in lower drug
tolerance levels, and the post-release community context, which often includes a lack of social
support and economic resources, also increases risk post-release. Linkage to treatment and
adoption of harm reduction strategies have proven to lower overdose risk, but little uptake of
these types of programs in correctional settings has taken place (Langendam et al., 2001).
Harm reduction and opioid overdose prevention efforts
Harm reduction approaches are strategies that have been proven effective at reducing overdose,
decreasing substance use and increasing retention in treatment (Fullerton et al., 2014). Examples of
harm reduction include: medication assisted treatment (MAT) such as naltrexone, methadone and
buprenorphine; safe injection facilities; overdose and substance use education; naloxone distribution;
and syringe exchange programs, among others. In response to the recent opioid epidemic, many
federal and state level harm reduction initiatives have been developed. For instance, the Obama
White House recently proposed a budget that includes $920 million for states to expand access to
MAT for those with opioid use disorder. The Obama White House also called on federal agencies
to work together in areas of education, monitoring, medication disposal, and enforcement in order to
reduce drug use and overdose rates. In addition, Congress and several federal agencies have
responded by educating and providing technical support to their constituencies to spur the
development of overdose prevention strategies. In states and localities where overdose rates are
particularly high, governors and mayors have formed task forces charged with developing legislative,
policy, and programmatic solutions to curb opioid overdose. For instance, in New York, the Ithaca
Plan was launched in 2015, and includes recommendations for establishing a “24-hour crisis center”
where people can obtain MAT and case management services, as well as creating the first safe
injection site in the USA. However, even though the strategies included in this plan are wide reaching
it does not include any corrections-based recommendations (Wilkinson and Fan, 2016).
Internationally, and especially in Europe, there are many examples of prison-based substance
use prevention programs, however the availability and use of harm reduction strategies varies
(Sander et al., 2016). In the USA few jails and prisons have harm reduction programs and, to our
knowledge, one of the only states in the USA that has explicitly incorporated corrections-based
recommendations into their overdose reduction strategy is Rhode Island (RI). The governor of RI
recently created the Overdose Prevention and Intervention Task Force that includes a variety of
cross-sector partnerships with the goal of reducing opioid overdose deaths by one-third within
three years. A major initiative outlined in the plan was a comprehensive MAT program at the RI
Department of Corrections that includes offering all three available MAT options (methadone,
buprenorphine, and naltrexone) during incarceration and linkage to continued treatment in the
community post-release (Green et al., 2015).
Harm reduction approaches are especially important for individuals with criminal justice
experience. Strategies that prioritize arresting and incarcerating drug users do not deter
substance use (Green and Winik, 2010). In contrast, such strategies imperil long-term outcomes
for drug users, because the fear of arrest and incarceration drives drug use “underground” and
discourages the utilization of health care services vital in mitigating the risk of overdose and
infectious disease transmission (Cloud and Davis, 2015). However, adoption of harm reduction in
criminal justice settings is inconsistent and depends largely on the type of facility (jail vs prison vs
diversion program) and local and state policies. Further, while law enforcement agencies
are increasingly equipping officers with naloxone, few jurisdictions are taking steps to distribute
the antidote or provide overdose prevention training to people exiting correctional facilities,
despite the significantly elevated risk of overdose during community re-entry.
Recommendations
Given the increased risk of overdose among those with recent criminal justice involvement and
the lack of available harm reduction-oriented services available in correctional settings, we
suggest a number of strategies be routinely deployed. Specifically we suggest: an expansion of
overdose education and naloxone distribution (OEND) programs for those at increased risk of
both opioid overdose and witnessing an overdose, the establishment of comprehensive MAT
programs as standard of care in correctional facilities, development of strategies for targeted
screening of overdose risk at discharge, and collaboration with community-based treatment
providers to link individuals to treatment post-release.
Expansion of OEND programs
The adoption of OEND programs is vital to addressing the opioid epidemic nationwide and
corrections-based OEND programs must be a component of any jurisdiction’s comprehensive
plan to address overdoses in their community. Naloxone, commonly referred to as Narcan,
is a highly effective, safe, and inexpensive drug that can be administered intravenously,
intramuscularly, or through a nasal spray to quickly resuscitate an individual experiencing
respiratory failure due to an opioid overdose. In recent years, a growing number of states have
passed laws to increase access to naloxone for first-responders and lay persons who are likely to
witness an overdose. Despite the fact that jails and prisons in the USA present a unique
opportunity to distribute naloxone to those at increased risk of both opioid overdose and
witnessing an overdose, the provision of naloxone to people upon release from correctional
settings is rare.
There are emerging international and domestic models for OEND as part of pre-release
programming at correctional facilities. In the USA, a small number of community-based or public
health funded OEND programs have forged relationships with correctional facilities to provide
overdose education, and, in some instances, distribute naloxone upon release. For example, the
New York State Department of Health AIDS Institute, New York State Department of Corrections
and Community Supervision, and the Harm Reduction Coalition launched an OEND program in the
Queensboro Correctional Facility that educates individuals preparing for re-entry about the risks of
opioid use after periods of incarceration and trains them to administer naloxone in the event that
they witness an overdose (Zucker et al., 2015). As more jurisdictions consider incorporating OEND
into their correctional facilities, however, it is critical that jails – with large populations of individuals
awaiting trial or serving shorter sentences – also be included in expansion efforts. Although shorter
sentences and unpredictable release dates present some challenges for implementing OEND, the
opportunity to reach this large, high-risk population cannot be missed.
Establish comprehensive MAT programs as standard of care
MAT, particularly in conjunction with adjunct psychosocial or behavioral interventions, is the most
effective evidence-based approach to address opioid use disorder (Connock et al., 2007).
Numerous studies have documented far-reaching benefits to implementing MAT in correctional
populations including post-incarceration reductions in illicit opioid use and reduced levels of
reincarceration (Sharma et al., 2016).
In some European countries (e.g. Switzerland) correctional access to MAT is routine
(Favrod-Coune et al., 2013). In the USA, however, there are over 3,200 local and county jails
and 1,800 state and federal prisons, but few facilities offer addiction treatment using MAT with
methadone, buprenorphine and/or naltrexone (Vestal, 2016). Among facilities that do offer MAT,
the majority restrict treatment to persons who are pregnant or to those who were engaged in
methadone treatment prior to incarceration, and it is usually only provided on an accelerated
30-day taper protocol (Rich et al., 2015). We recommend that comprehensive MAT programs
that offer naltrexone, buprenorphine, and methadone be standard of care in correctional facilities.
These programs should include: screening all individuals for opioid use disorder; continuing and
initiating individuals on MAT while incarcerated; offering all three currently available MAT options
as clinically appropriate; and linkage to community MAT programs post-release.
Development of overdose risk screening at discharge
Whereas the connection between incarceration and overdose has been well established, less is
known about the factors specific to incarceration or the post-release environment that may
exacerbate risk. Some work relevant to the context of overdose in the community has identified
lack of social support, financial deprivation, and ever-present exposure to drugs as factors that
can impact risk (Binswanger et al., 2012). Fewer studies, though, have explored the institutional
and individual level features of incarceration that might increase risk, and we suggest further study
of these factors is needed.
There are numerous assessment tools that gauge risk of drug use and addiction, but very few
overdose risk indexes (Zedler et al., 2015), and even fewer that are adapted for criminal justice
involved populations. Therefore, there is a need to develop a targeted overdose risk assessment
tool for those nearing release from correctional facilities. Future research is needed to determine
the factors that should be included, who should assess these factors (nurses, correctional
administrators, social workers) and what is the best time period to administer the assessment
(e.g. at intake vs at release). Based on previous research we suggest taking the following factors
into consideration: history of homelessness, lack of social support, previous overdose, intention
to return to opioid use post-release, history of financial hardship, and other relevant community
and institutional level variables. If an individual is deemed “at risk” he or she should be provided
with enhanced discharge planning and treatment, which could include intensive case
management and wrap-around services that might mitigate risk of future overdose.
Collaboration with community-based providers
An important part of overdose prevention among people with criminal justice experience is
collaborating with community-based partners so that treatment can be optimized. For instance, if
correctional agencies are reluctant to administer MAT, contracting with a community-based
substance use treatment organization that has expertise in delivering MAT may make
implementation much more feasible. In addition, correctional administrators must work in
concert with community-based partners to link recently incarcerated individuals to substance use
treatment, syringe exchange programs, safe injection facilities (where available) and other important
re-entry services post-release. Safe injection staff should also work with regional correctional
facilities to ensure that individuals at risk for overdose are aware of safe injection sites prior to
release. We also recommend creating re-entry programs that utilize peer-based models such as
employing community health workers who are in recovery from a substance-use disorder and have
prior experience with incarceration to deliver services; doing so can improve trust and clinical
rapport, and increase utilization of vital health services upon release.
Conclusions
Individuals with criminal justice experience are disproportionately at risk of opioid overdose. However,
very few harm reduction oriented approaches to reduce overdose risk are implemented in prisons
and jails. State and local governments seeking comprehensive, interagency strategies to curb the
incidence of overdose morbidity and mortality have so far overlooked the value of implementing harm
reduction interventions in correctional settings. We recommend: an expansion of OEND programs,
the establishment of comprehensiveMAT programs as standard of care, the development and use of
overdose risk assessment tools to identify the incarceration-related factors that increase risk. We
acknowledge that implementing harm reduction strategies in criminal justice settings takes political
will, public support, and earmarked funding, which may be lacking in several areas across the
country. However, as public awareness about the opioid epidemic grows, there are opportunities for
coalition-building and investment. In the USA, the Bureau of Justice Assistance’s Residential
Substance Abuse Treatment for State Prisoners formula grant program is advocating for corrections-
based MAT programming. The RI overdose prevention plan also recently resulted in two million
dollars of state funding, approved by the legislature, to be used for MAT in state corrections.
Continuing to look to other countries, states or systems that have implemented harm reduction
programs in correctional settings can provide a blueprint for the creation of future initiatives.
Summary of major takeaways:
■ those with criminal justice involvement experience disproportionately higher rates of fatal and
non-fatal overdose;
■ harm reduction strategies are vital for reducing the risk of overdose in the post-release
community; and
■ we recommend that the following be implemented in correctional settings: expansion of
overdose education and naloxone programs; establishment of comprehensive MAT programs
as standard of care; development of corrections-specific overdose risk assessment tools; and
increased collaboration between corrections entities and community-based organizations.
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